The U.S. Food and Drug administration is near approving about 10 million Johnson & Johnson (JNJ.N) COVID-19 vaccine doses made at a troubled plant in Baltimore, a NCS reporter stated in a put up on Twitter citing an unnamed supply.
The well being regulator has been reviewing batches of doses made at Emergent’s (EBS.N) plant in Baltimore, Maryland, NCS stated, including that the company will not be but prepared to totally clear the power following manufacturing points there.
Representatives for the FDA didn’t instantly response to requests for remark. J&J had no touch upon the report.
(*10*)Our Standards: The Thomson Reuters Trust Principles.